#  @TuHURAIR TuHURA IR TuHURA IR posts on X about $hura, in the, stage, address the most. They currently have [--] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::2006457119487475712/interactions)  - [--] Week [---] -90% ### Mentions: [--] [#](/creator/twitter::2006457119487475712/posts_active)  - [--] Week [--] -70% ### Followers: [--] [#](/creator/twitter::2006457119487475712/followers)  - [--] Week [--] +100% ### CreatorRank: undefined [#](/creator/twitter::2006457119487475712/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) **Social topic influence** [$hura](/topic/$hura) #14, [in the](/topic/in-the), [stage](/topic/stage), [address](/topic/address), [longterm](/topic/longterm), [knowledge](/topic/knowledge), [we are](/topic/we-are), [the only](/topic/the-only), [based](/topic/based), [future](/topic/future) ### Top Social Posts Top posts by engagements in the last [--] hours "$HURA Effective immune responses against cancer are often limited by multiple suppressive signals acting at the same time. Our approach is designed to address this challenge through a coordinated dual mechanism" [X Link](https://x.com/TuHURAIR/status/2014774539947786286) 2026-01-23T18:57Z [--] followers, [--] engagements "$HURA Together these mechanisms are designed to reduce immune suppression while enabling immune activation. Rather than relying on a single pathway this strategy aims to reshape the immune landscape around the tumor" [X Link](https://x.com/TuHURAIR/status/2014774544049885511) 2026-01-23T18:57Z [--] followers, [--] engagements "$HURA We view this dual-action design as a key strength of our platform. For those interested in the science behind this approach we invite you to watch the video linked below. https://www.youtube.com/shorts/jfTnJQYPraQ https://www.youtube.com/shorts/jfTnJQYPraQ" [X Link](https://x.com/TuHURAIR/status/2014774546205647066) 2026-01-23T18:57Z [--] followers, [---] engagements "$HURA Innovation in oncology is increasingly defined by differentiation not just efficacy. Our ADC program is built around a strategy that to our knowledge is unique in the field" [X Link](https://x.com/anyuser/status/2015847491564982513) 2026-01-26T18:01Z [--] followers, [---] engagements "$HURA Unlike conventional ADCs our approach does not deliver toxic payloads or target tumor cells directly. Instead it focuses on the tumor microenvironment targeting immune suppression via the delta opioid receptor linked to a VISTA-enabling antibody" [X Link](https://x.com/TuHURAIR/status/2015847493548827001) 2026-01-26T18:01Z [--] followers, [--] engagements "$HURA Based on our review of existing scientific literature we believe we are the only group advancing this specific combination and mechanism placing our program in a distinct category within immuno-oncology" [X Link](https://x.com/anyuser/status/2015847495608291521) 2026-01-26T18:01Z [--] followers, [---] engagements "$HURA This differentiated positioning supports potential complementarity with existing therapies and aims to address unmet needs through a novel pathway. We remain confident in the scientific rationale and look forward to sharing future milestones" [X Link](https://x.com/anyuser/status/2015847497982157200) 2026-01-26T18:01Z [--] followers, [---] engagements "$HURA From a capital markets perspective value in biotechnology is increasingly driven by platforms that can open new therapeutic categories rather than incremental improvements on existing ones" [X Link](https://x.com/anyuser/status/2016572238510592453) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA Our ADC program represents a platform-level opportunity built around a novel mechanism of action. By targeting immune suppression in the tumor microenvironment rather than tumor cells directly this approach has the potential to expand ADC utility" [X Link](https://x.com/TuHURAIR/status/2016572241207521586) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA This non-cytotoxic design also creates optionality for combination strategies and broader clinical applications. Importantly this differentiation supports clearer positioning within a competitive landscape of similar mechanisms" [X Link](https://x.com/anyuser/status/2016572244168712536) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA We believe this platform-driven approach strengthens the investment thesis and supports long-term value creation as milestones are reached. We welcome questions from the investment community and encourage interested parties to connect with us" [X Link](https://x.com/anyuser/status/2016572246857277584) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA IFx [---] continues to build strategic momentum as a late stage immuno oncology asset. With a Phase [--] registration accelerated approval trial already underway in Merkel Cell Carcinoma the program demonstrates expanding clinical and regulatory relevance" [X Link](https://x.com/anyuser/status/2022405963760963670) 2026-02-13T20:22Z [--] followers, [--] engagements "$HURA Human proof of concept in checkpoint inhibitor refractory patients strengthens the case for multi indication expansion and combination driven value creation. This profile supports a platform level opportunity rather than a single indication outcome" [X Link](https://x.com/anyuser/status/2022405966525010302) 2026-02-13T20:22Z [--] followers, [--] engagements "$HURA IFx [---] continues to build strategic momentum as a late stage immuno oncology asset. With a Phase [--] registration accelerated approval trial already underway in Merkel Cell Carcinoma the program demonstrates expanding clinical and regulatory relevance" [X Link](https://x.com/anyuser/status/2022405963760963670) 2026-02-13T20:22Z [--] followers, [--] engagements "$HURA Human proof of concept in checkpoint inhibitor refractory patients strengthens the case for multi indication expansion and combination driven value creation. This profile supports a platform level opportunity rather than a single indication outcome" [X Link](https://x.com/anyuser/status/2022405966525010302) 2026-02-13T20:22Z [--] followers, [--] engagements "$HURA As TuHURA advances a diversified pipeline including TBS [----] its VISTA inhibiting antibody and its first-in-class bifunctional bispecifc immune modulating ADC programs IFx [---] stands out as a core value driver with meaningful long term upside" [X Link](https://x.com/anyuser/status/2022405969121284341) 2026-02-13T20:22Z [--] followers, [--] engagements "$HURA IFx [---] targets primary resistance to checkpoint inhibitors in advanced melanoma by priming the innate immune system and activating tumor specific cytotoxic T cells enabling renewed response to anti PD(L)-1 LAG3 or CTLA-4 therapies" [X Link](https://x.com/anyuser/status/2022100121237041312) 2026-02-13T00:06Z [--] followers, [--] engagements "$HURA In a completed Phase [--] study published in Molecular Therapeutics IFx [---] showed a favorable safety profile with no serious dose limiting toxicities and renewed clinical benefit in patients previously progressed on anti PD1 therapy" [X Link](https://x.com/anyuser/status/2022100122583412816) 2026-02-13T00:06Z [--] followers, [--] engagements "$HURA Recent regulatory progress highlights TuHURAs continued focus on advancing its immuno-oncology platform. The Phase [--] registration-directed trial in Merkel cell carcinoma remains a central priority with site activation and enrollment progressing" [X Link](https://x.com/anyuser/status/2019473122739503279) 2026-02-05T18:08Z [--] followers, [---] engagements "$HURA At the same time Orphan Drug Designation in melanoma expands the potential scope of IFx [---] without diverting resources from ongoing trials. This reflects a platform-driven approach where scientific validation in one indication supports broader development opportunities" [X Link](https://x.com/anyuser/status/2019473124899639481) 2026-02-05T18:08Z [--] followers, [---] engagements "$HURA TuHURA remains focused on execution data generation and transparent communication as programs advance" [X Link](https://x.com/anyuser/status/2019473127042883628) 2026-02-05T18:08Z [--] followers, [---] engagements "$HURA Orphan Drug Designation is granted to therapies that address serious conditions affecting limited patient populations" [X Link](https://x.com/anyuser/status/2019114095744807342) 2026-02-04T18:21Z [--] followers, [--] engagements "$HURA For IFx [---] in melanoma this designation reflects: Recognition of unmet need Support for continued development Enhanced regulatory engagement Potential commercial protections if approved" [X Link](https://x.com/anyuser/status/2019114098190086576) 2026-02-04T18:21Z [--] followers, [--] engagements "$HURA While Orphan Drug Designation does not replace clinical data requirements it strengthens the development pathway and improves long-term program visibility. HURA continues to advance IFx [---] through defined milestones with regulatory and scientific rigor guiding each stage" [X Link](https://x.com/anyuser/status/2019114100660531386) 2026-02-04T18:21Z [--] followers, [--] engagements "$HURA TuHURA Biosciences has received FDA Orphan Drug Designation for IFx [---] in the treatment of Stage IIB to Stage IV cutaneous melanoma" [X Link](https://x.com/anyuser/status/2018762402053947872) 2026-02-03T19:03Z [--] followers, [---] engagements "$HURA Orphan Drug Designation provides regulatory incentives that can support development efficiency including market exclusivity and potential fee reductions. This milestone strengthens the foundation of the IFx platform while Phase [--] continues in Merkel cell carcinoma" [X Link](https://x.com/anyuser/status/2018762406566977925) 2026-02-03T19:03Z [--] followers, [---] engagements "$HURA Together these advances reinforce TuHURAs strategy of building value through disciplined clinical execution and regulatory alignment" [X Link](https://x.com/anyuser/status/2018762409062838584) 2026-02-03T19:03Z [--] followers, [---] engagements "$HURA From a capital markets perspective value in biotechnology is increasingly driven by platforms that can open new therapeutic categories rather than incremental improvements on existing ones" [X Link](https://x.com/anyuser/status/2016572238510592453) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA This non-cytotoxic design also creates optionality for combination strategies and broader clinical applications. Importantly this differentiation supports clearer positioning within a competitive landscape of similar mechanisms" [X Link](https://x.com/anyuser/status/2016572244168712536) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA We believe this platform-driven approach strengthens the investment thesis and supports long-term value creation as milestones are reached. We welcome questions from the investment community and encourage interested parties to connect with us" [X Link](https://x.com/anyuser/status/2016572246857277584) 2026-01-28T18:01Z [--] followers, [---] engagements "$HURA Innovation in oncology is increasingly defined by differentiation not just efficacy. Our ADC program is built around a strategy that to our knowledge is unique in the field" [X Link](https://x.com/anyuser/status/2015847491564982513) 2026-01-26T18:01Z [--] followers, [---] engagements "$HURA Based on our review of existing scientific literature we believe we are the only group advancing this specific combination and mechanism placing our program in a distinct category within immuno-oncology" [X Link](https://x.com/anyuser/status/2015847495608291521) 2026-01-26T18:01Z [--] followers, [---] engagements "$HURA This differentiated positioning supports potential complementarity with existing therapies and aims to address unmet needs through a novel pathway. We remain confident in the scientific rationale and look forward to sharing future milestones" [X Link](https://x.com/anyuser/status/2015847497982157200) 2026-01-26T18:01Z [--] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@TuHURAIR TuHURA IR
TuHURA IR posts on X about $hura, in the, stage, address the most. They currently have [--] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [---] -90%
Mentions: [--] #
- [--] Week [--] -70%
Followers: [--] #
- [--] Week [--] +100%
CreatorRank: undefined #
Social Influence
Social category influence finance
Social topic influence $hura #14, in the, stage, address, longterm, knowledge, we are, the only, based, future
Top Social Posts
Top posts by engagements in the last [--] hours
"$HURA Effective immune responses against cancer are often limited by multiple suppressive signals acting at the same time. Our approach is designed to address this challenge through a coordinated dual mechanism"
X Link 2026-01-23T18:57Z [--] followers, [--] engagements
"$HURA Together these mechanisms are designed to reduce immune suppression while enabling immune activation. Rather than relying on a single pathway this strategy aims to reshape the immune landscape around the tumor"
X Link 2026-01-23T18:57Z [--] followers, [--] engagements
"$HURA We view this dual-action design as a key strength of our platform. For those interested in the science behind this approach we invite you to watch the video linked below. https://www.youtube.com/shorts/jfTnJQYPraQ https://www.youtube.com/shorts/jfTnJQYPraQ"
X Link 2026-01-23T18:57Z [--] followers, [---] engagements
"$HURA Innovation in oncology is increasingly defined by differentiation not just efficacy. Our ADC program is built around a strategy that to our knowledge is unique in the field"
X Link 2026-01-26T18:01Z [--] followers, [---] engagements
"$HURA Unlike conventional ADCs our approach does not deliver toxic payloads or target tumor cells directly. Instead it focuses on the tumor microenvironment targeting immune suppression via the delta opioid receptor linked to a VISTA-enabling antibody"
X Link 2026-01-26T18:01Z [--] followers, [--] engagements
"$HURA Based on our review of existing scientific literature we believe we are the only group advancing this specific combination and mechanism placing our program in a distinct category within immuno-oncology"
X Link 2026-01-26T18:01Z [--] followers, [---] engagements
"$HURA This differentiated positioning supports potential complementarity with existing therapies and aims to address unmet needs through a novel pathway. We remain confident in the scientific rationale and look forward to sharing future milestones"
X Link 2026-01-26T18:01Z [--] followers, [---] engagements
"$HURA From a capital markets perspective value in biotechnology is increasingly driven by platforms that can open new therapeutic categories rather than incremental improvements on existing ones"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA Our ADC program represents a platform-level opportunity built around a novel mechanism of action. By targeting immune suppression in the tumor microenvironment rather than tumor cells directly this approach has the potential to expand ADC utility"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA This non-cytotoxic design also creates optionality for combination strategies and broader clinical applications. Importantly this differentiation supports clearer positioning within a competitive landscape of similar mechanisms"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA We believe this platform-driven approach strengthens the investment thesis and supports long-term value creation as milestones are reached. We welcome questions from the investment community and encourage interested parties to connect with us"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA IFx [---] continues to build strategic momentum as a late stage immuno oncology asset. With a Phase [--] registration accelerated approval trial already underway in Merkel Cell Carcinoma the program demonstrates expanding clinical and regulatory relevance"
X Link 2026-02-13T20:22Z [--] followers, [--] engagements
"$HURA Human proof of concept in checkpoint inhibitor refractory patients strengthens the case for multi indication expansion and combination driven value creation. This profile supports a platform level opportunity rather than a single indication outcome"
X Link 2026-02-13T20:22Z [--] followers, [--] engagements
"$HURA IFx [---] continues to build strategic momentum as a late stage immuno oncology asset. With a Phase [--] registration accelerated approval trial already underway in Merkel Cell Carcinoma the program demonstrates expanding clinical and regulatory relevance"
X Link 2026-02-13T20:22Z [--] followers, [--] engagements
"$HURA Human proof of concept in checkpoint inhibitor refractory patients strengthens the case for multi indication expansion and combination driven value creation. This profile supports a platform level opportunity rather than a single indication outcome"
X Link 2026-02-13T20:22Z [--] followers, [--] engagements
"$HURA As TuHURA advances a diversified pipeline including TBS [----] its VISTA inhibiting antibody and its first-in-class bifunctional bispecifc immune modulating ADC programs IFx [---] stands out as a core value driver with meaningful long term upside"
X Link 2026-02-13T20:22Z [--] followers, [--] engagements
"$HURA IFx [---] targets primary resistance to checkpoint inhibitors in advanced melanoma by priming the innate immune system and activating tumor specific cytotoxic T cells enabling renewed response to anti PD(L)-1 LAG3 or CTLA-4 therapies"
X Link 2026-02-13T00:06Z [--] followers, [--] engagements
"$HURA In a completed Phase [--] study published in Molecular Therapeutics IFx [---] showed a favorable safety profile with no serious dose limiting toxicities and renewed clinical benefit in patients previously progressed on anti PD1 therapy"
X Link 2026-02-13T00:06Z [--] followers, [--] engagements
"$HURA Recent regulatory progress highlights TuHURAs continued focus on advancing its immuno-oncology platform. The Phase [--] registration-directed trial in Merkel cell carcinoma remains a central priority with site activation and enrollment progressing"
X Link 2026-02-05T18:08Z [--] followers, [---] engagements
"$HURA At the same time Orphan Drug Designation in melanoma expands the potential scope of IFx [---] without diverting resources from ongoing trials. This reflects a platform-driven approach where scientific validation in one indication supports broader development opportunities"
X Link 2026-02-05T18:08Z [--] followers, [---] engagements
"$HURA TuHURA remains focused on execution data generation and transparent communication as programs advance"
X Link 2026-02-05T18:08Z [--] followers, [---] engagements
"$HURA Orphan Drug Designation is granted to therapies that address serious conditions affecting limited patient populations"
X Link 2026-02-04T18:21Z [--] followers, [--] engagements
"$HURA For IFx [---] in melanoma this designation reflects: Recognition of unmet need Support for continued development Enhanced regulatory engagement Potential commercial protections if approved"
X Link 2026-02-04T18:21Z [--] followers, [--] engagements
"$HURA While Orphan Drug Designation does not replace clinical data requirements it strengthens the development pathway and improves long-term program visibility. HURA continues to advance IFx [---] through defined milestones with regulatory and scientific rigor guiding each stage"
X Link 2026-02-04T18:21Z [--] followers, [--] engagements
"$HURA TuHURA Biosciences has received FDA Orphan Drug Designation for IFx [---] in the treatment of Stage IIB to Stage IV cutaneous melanoma"
X Link 2026-02-03T19:03Z [--] followers, [---] engagements
"$HURA Orphan Drug Designation provides regulatory incentives that can support development efficiency including market exclusivity and potential fee reductions. This milestone strengthens the foundation of the IFx platform while Phase [--] continues in Merkel cell carcinoma"
X Link 2026-02-03T19:03Z [--] followers, [---] engagements
"$HURA Together these advances reinforce TuHURAs strategy of building value through disciplined clinical execution and regulatory alignment"
X Link 2026-02-03T19:03Z [--] followers, [---] engagements
"$HURA From a capital markets perspective value in biotechnology is increasingly driven by platforms that can open new therapeutic categories rather than incremental improvements on existing ones"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA This non-cytotoxic design also creates optionality for combination strategies and broader clinical applications. Importantly this differentiation supports clearer positioning within a competitive landscape of similar mechanisms"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA We believe this platform-driven approach strengthens the investment thesis and supports long-term value creation as milestones are reached. We welcome questions from the investment community and encourage interested parties to connect with us"
X Link 2026-01-28T18:01Z [--] followers, [---] engagements
"$HURA Innovation in oncology is increasingly defined by differentiation not just efficacy. Our ADC program is built around a strategy that to our knowledge is unique in the field"
X Link 2026-01-26T18:01Z [--] followers, [---] engagements
"$HURA Based on our review of existing scientific literature we believe we are the only group advancing this specific combination and mechanism placing our program in a distinct category within immuno-oncology"
X Link 2026-01-26T18:01Z [--] followers, [---] engagements
"$HURA This differentiated positioning supports potential complementarity with existing therapies and aims to address unmet needs through a novel pathway. We remain confident in the scientific rationale and look forward to sharing future milestones"
X Link 2026-01-26T18:01Z [--] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing